Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 26.71 USD 1.33% Market Closed
Market Cap: 151.4B USD
Have any thoughts about
Pfizer Inc?
Write Note

Pfizer Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pfizer Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Cash from Operating Activities
$8B
CAGR 3-Years
-37%
CAGR 5-Years
-10%
CAGR 10-Years
-7%
Johnson & Johnson
NYSE:JNJ
Cash from Operating Activities
$25.1B
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Operating Activities
$15B
CAGR 3-Years
-1%
CAGR 5-Years
12%
CAGR 10-Years
14%
Merck & Co Inc
NYSE:MRK
Cash from Operating Activities
$18.3B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
4%
Zoetis Inc
NYSE:ZTS
Cash from Operating Activities
$2.9B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
19%
Eli Lilly and Co
NYSE:LLY
Cash from Operating Activities
$6B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
2%
No Stocks Found

Pfizer Inc
Glance View

Market Cap
151.4B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.

PFE Intrinsic Value
24.86 USD
Overvaluation 7%
Intrinsic Value
Price

See Also

What is Pfizer Inc's Cash from Operating Activities?
Cash from Operating Activities
8B USD

Based on the financial report for Sep 29, 2024, Pfizer Inc's Cash from Operating Activities amounts to 8B USD.

What is Pfizer Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-7%

Over the last year, the Cash from Operating Activities growth was -34%. The average annual Cash from Operating Activities growth rates for Pfizer Inc have been -37% over the past three years , -10% over the past five years , and -7% over the past ten years .

Back to Top